🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Phanes Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA register with Phanes Therapeutics as lead sponsor. Synced 26 Sep 2026
3Current trials
3Recruiting now
17Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Phanes Therapeutics is the lead sponsor of 3 current clinical trials in our USA register. 3 are recruiting patients now. All registered phases are Phase 1/2. The drugs named most often in its trials are Carboplatin, Gemcitabine and Paclitaxel. The most-studied condition is Pancreatic Ductal Adenocarcinoma.

ClinicalTrials.gov trials by status

  • Recruiting3100%

Trials by phase

  • Phase 1/23100%
01

Clinical trials sponsored by Phanes Therapeutics

3 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Phase 1/2 Recruiting 2023-03 USA
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)
Phase 1/2 Recruiting 2023-09 USA
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
NCT05431270 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Phase 1/2 Recruiting 2022-08 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Phanes Therapeutics trials

17 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Phanes Therapeutics trials

8 conditions
Pancreatic Ductal Adenocarcinoma2Gastric or Gastroesophageal Junction Adenocarcinoma1Biliary Tract Cancer (BTC)1Small Cell Lung Cancer (SCLC)1Large Cell Neuroendocrine Cancer (LCNEC)1Neuroendocrine Prostate Cancer (NEPC)1Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)1Non Small Cell Lung Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA33

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Pancreatic Ductal Adenocarcinoma

SponsorTrials
Perspective Therapeutics1
Astellas Pharma1
Chipscreen Biosciences1

Sponsors with the most current trials registered for this condition.

06

Questions about Phanes Therapeutics trials

How many clinical trials does Phanes Therapeutics sponsor?

Phanes Therapeutics is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Phanes Therapeutics trials recruiting?

Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Phanes Therapeutics testing?

Its current trials name 17 drugs and biologicals as interventions. The most frequent are Carboplatin (2), Gemcitabine (2), Paclitaxel (2), Pembrolizumab (2) and Abraxane (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.